Associated Papers
Ancestry and somatic profile indicate acral melanoma origin and prognosis.
Basurto-Lozada P et al.
Nature, 2026
SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma.
Brown C et al.
Cells, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.
Manabe T et al.
Research Square, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal Cancer.
Xie L et al.
Molecules (basel, Switzerland), 2025
Ancestry and somatic profile predict acral melanoma origin and prognosis.
Basurto-Lozada P et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Aggressive nodular melanoma: case report with an unusual BRAF mutation.
El Bardai S et al.
Molecular Biology Reports, 2025
Dr. Kinase: predicting the drug-resistance hotspots of protein kinases.
Lin S et al.
Nucleic Acids Research, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors.
Chan HT et al.
Clinical Chemistry, 2025
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment.
Amagai R et al.
The Journal of Dermatology, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 Alterations.
Odintsov I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.
Kemps PG et al.
Blood Advances, 2025
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS).
Taniguchi H et al.
Cancers, 2025
Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold.
Wan X et al.
Theranostics, 2025
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting.
Wallen ZD et al.
Frontiers in Genetics, 2025
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.
Bortolot M et al.
International Journal of Molecular Sciences, 2024
Recapitulating the adenoma-carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids.
Mizutani T et al.
Nature Cancer, 2024
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
Cai X et al.
Bmc Cancer, 2024
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.
Li H et al.
Npj Precision Oncology, 2024
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Li Y et al.
Esmo Open, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Yaeger R et al.
Cancer Discovery, 2024
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.
Chaudhary HA et al.
Drugs in R&d, 2024
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
Kuehn JC et al.
Npj Precision Oncology, 2024
Pathways and targeting avenues of BRAF in non-small cell lung cancer.
Imyanitov EN et al.
Expert Opinion on Therapeutic Targets, 2024
BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience.
Fei F et al.
International Journal of Molecular Sciences, 2024
Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T et al.
Cancer Medicine, 2024
Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing.
George GV et al.
Genes, 2024
Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms.
Kemps PG et al.
Histopathology, 2024
Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations.
Hu J et al.
Neoplasia (new York, N.y.), 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
Jiang L et al.
Journal of Cancer Research and Clinical Oncology, 2024
A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.
Zarabi SK et al.
Biomolecules, 2024
RET splice site variants in medullary thyroid carcinoma.
Saeed-Vafa D et al.
Frontiers in Genetics, 2024
Biomarker testing in lung cancer: from bench to bedside.
Batra U et al.
Oncology Reviews, 2024
Treatment outcomes of patients with BRAFV600E-mutated metastatic colorectal cancer: a Polish retrospective cohort study.
Żok J et al.
Contemporary Oncology (poznan, Poland), 2024